Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.

Allurion Technologies shares soared 200% Friday as it planned to test its gastric balloon with the key ingredient in popular ...

Allurion Technologies (ALUR) stock climbed 200% despite a ~7.4M stock and warrants offering announced by the company. Read ...

Allurion Technologies (NYSE: ALUR) shares are moving higher Friday potentially after after the company announced plans to conduct a clinical study evaluating the combination of its Allurion Program ...

The Allurion swallowable intragastric balloon offers a safe, effective and minimally invasive method of losing weight.

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a definitive ...

NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a ...